Results 61 to 70 of about 10,789,024 (363)

Lipoprotein(a) in Cardiovascular Diseases [PDF]

open access: yesBioMed Research International, 2013
Lipoprotein(a) (Lp(a)) is an LDL-like molecule consisting of an apolipoprotein B-100 (apo(B-100)) particle attached by a disulphide bridge to apo(a). Many observations have pointed out that Lp(a) levels may be a risk factor for cardiovascular diseases.
Malaguarnera M   +9 more
openaire   +3 more sources

Circulating histones as clinical biomarkers in critically ill conditions

open access: yesFEBS Letters, EarlyView.
Circulating histones are emerging as promising biomarkers in critical illness due to their diagnostic, prognostic, and therapeutic potential. Detection methods such as ELISA and mass spectrometry provide reliable approaches for quantifying histone levels in plasma samples.
José Luis García‐Gimenez   +17 more
wiley   +1 more source

Total protein intake and subsequent risk of chronic kidney disease: the Circulatory Risk in Communities Study

open access: yesEnvironmental Health and Preventive Medicine, 2023
Background: Whether dietary protein intake worsens renal function in the general population has been discussed but not yet determined. We aimed to examine the longitudinal association between dietary protein intake and risk of incident chronic kidney ...
Sachimi Kubo   +13 more
doaj   +1 more source

Nutrition and cardiovascular disease [PDF]

open access: yesArteriosclerosis, Thrombosis, and Vascular Biology, 2007
This chapter looks at the correlation between nutrition and cardiovascular disease. The most common and pertinent cardiovascular diseases are myocardial infarction, stroke, peripheral vascular disease, and hypertension, which serve as a major risk factor for myocardial infarction and stroke.
Godfrey S. Getz, Catherine A. Reardon
openaire   +2 more sources

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

open access: yesMolecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi   +6 more
wiley   +1 more source

Current status and etiology of valvular heart disease in China: a population-based survey

open access: yesBMC Cardiovascular Disorders, 2021
Background The epidemiology of valvular heart disease (VHD) has changed markedly over the last 50 years worldwide, and the prevalence and features of VHD in China are unknown. The objective of this study was to investigate the current status and etiology
Ying Yang   +10 more
doaj   +1 more source

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

open access: yesCirculation, 2003
In 1998, the American Heart Association convened Prevention Conference V to examine strategies for the identification of high-risk patients who need primary prevention.
T. Pearson   +14 more
semanticscholar   +1 more source

Plasma lipidomic and metabolomic profiles in high‐grade glioma patients before and after 72‐h presurgery water‐only fasting

open access: yesMolecular Oncology, EarlyView.
Presurgery 72‐h fasting in GB patients leads to adaptations of plasma lipids and polar metabolites. Fasting reduces lysophosphatidylcholines and increases free fatty acids, shifts triglycerides toward long‐chain TGs and increases branched‐chain amino acids, alpha aminobutyric acid, and uric acid.
Iris Divé   +7 more
wiley   +1 more source

Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?

open access: yesMolecular Oncology, EarlyView.
 
Chen‐xi Li, Zhong‐cheng Gong
wiley   +1 more source

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

open access: yesNew England Journal of Medicine, 2020
BACKGROUND Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower lipoprotein(a) levels.
S. Tsimikas   +14 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy